This is a StreetInsider.com Premium Only Page

(NCNA) – StreetInsider.com Reports

Mar 27, 2024 04:30 PM NuCana (NCNA) to Implement ADS Ratio Change

Oct 13, 2023 12:31 PM NuCana (NCNA) Presents Encouraging Data on NUC-3373 in Colorectal Cancer

May 12, 2023 04:01 PM NuCana (NCNA) Receives Nasdaq Notice

Mar 24, 2023 04:31 PM NuCana (NCNA) Issues Oral Ruling that NuCana’s ‘190 Patent is Not Valid

Jan 6, 2023 04:01 PM NuCana (NCNA) Announces Receipt of NASDAQ Notice

Nov 28, 2022 03:10 AM NuCana (NCNA) PT Lowered to $2 at Citi

Nov 21, 2022 07:33 AM NuCana (NCNA) PT Lowered to $4 at Oppenheimer

Oct 26, 2022 07:06 AM NuCana (NCNA) Presents Positive Data on NUC-3373

Sep 22, 2022 07:44 AM NuCana (NCNA) PT Lowered to $3 at Jefferies

Sep 12, 2022 10:52 AM NuCana (NCNA) Presents Promising NUC-7738 Data

Sep 12, 2022 08:03 AM NuCana (NCNA) Reports Favorable Data on NUC-3373

Jul 27, 2022 08:02 AM NuCana (NCNA) Regains Compliance with Nasdaq Minimum Bid Price

Jun 6, 2022 05:55 AM "Upcoming Data Announcement Could Support Outperformance" - Oppenheimer Bullish on NuCana (NCNA) with Outperform Rating and $5 Price Target

Jun 3, 2022 04:02 PM NuCana (NCNA) Receives Nasdaq Notice Regarding Minimum Bid Price

Apr 13, 2022 11:54 AM NuCana (NCNA) received a Notice of Allowance for its US patent application 16/769,635 - PatentGrants

Mar 14, 2022 06:15 AM NuCana (NCNA) PT Lowered to $5 at Oppenheimer

Mar 4, 2022 04:16 AM NuCana (NCNA) PT Lowered to $5 at Citi

Mar 3, 2022 06:25 AM Truist Securities Reiterates NuCana (NCNA) at Buy, NuTide:121 is Not Central to Thesis, Plenty of Cash Runway to Complete Other Studies

Mar 3, 2022 05:31 AM UPDATE: Cowen Downgrades NuCana (NCNA) to Market Perform

Mar 2, 2022 04:01 PM NuCana (NCNA) Phase 3 Biliary Tract Cancer Study is Being Discontinued

Mar 2, 2022 04:00 PM NuCana (NCNA) Halted, News Pending

Feb 22, 2022 04:01 PM NuCana (NCNA) Enrolls Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study

Feb 3, 2022 08:11 PM Increasing Comfort That NuCana's (NCNA) Phase 3 Data Will Perform to Expectations, Shares Are Compelling - Oppenheimer

Nov 1, 2021 04:39 PM NuCana (NCNA) Appoints Elliott M. Levy to its Board

Sep 29, 2021 08:01 AM NuCana (NCNA) Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Treatment of Biliary Tract Cancer

May 19, 2021 04:04 PM NuCana (NCNA) Reports Q1 Loss of GBP0.19

Mar 5, 2021 08:42 AM NuCana (NCNA) PT Lowered to $19 at Oppenheimer

Jan 15, 2021 08:06 AM NuCana (NCNA) Highlights Encouraging Data for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer

Dec 21, 2020 04:11 PM NuCana (NCNA) Adds Andrew Kay as Board Chair

Dec 1, 2020 09:25 AM Pre-Open Stock Movers 12/01: (BB) (MRNA) (KSS) Higher; (FOUR) (NOVA) (ZM) Lower (more...)

Nov 30, 2020 05:41 PM After-Hours Stock Movers 11/30: (CFII) (CAAS) (SPCE) Higher; (FOUR) (NOVA) (ZM) Lower (more...)

Nov 30, 2020 04:04 PM NuCana (NCNA) Announces Final Data from Phase Ib Study of Acelarin plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in The Oncologist

Nov 30, 2020 11:56 AM NuCana (NCNA) PT Lowered to $20 at Oppenheimer

Oct 22, 2020 09:22 AM Pre-Open Stock Movers 10/22: (ALGN) (BCOV) (LVS) Higher; (APTX) (AMSC) (CMG) Lower (more...)

Oct 22, 2020 09:13 AM Truist Securities Starts NuCana (NCNA) at Buy; 'Underappreciated Platform Company'

Sep 17, 2020 09:29 AM Pre-Open Movers 09/17: (SRNE) (MLHR) (RIGL) Higher; (SBBP) (NCNA) (SNOW) Lower (more...)

Sep 17, 2020 07:02 AM NuCana (NCNA) Prices 15.56M ADS Offering at $4.50/ADS

Sep 16, 2020 05:35 PM After-Hours Movers 9/16: (MLHR) (SCS) (MRNA) Higher; (SBBP) (NCNA) (FSLR) Lower (more...)

Sep 16, 2020 04:02 PM NuCana (NCNA) Announces Proposed Public Offering of ADSs

Aug 21, 2020 08:04 AM NuCana (NCNA) PT Raised to $21 at Oppenheimer

Aug 21, 2020 06:34 AM NuCana (NCNA) PT Raised to $17 at H.C. Wainwright

Jul 24, 2020 09:30 AM Pre-Open Stock Movers 07/24: (ABUS) (SKX) (AMD) Higher; (EHTH) (INTC) (TSLA) Lower (more...)

Jul 23, 2020 05:59 PM After-Hours Movers 07/23: (BJRI) (MAT) (AMD) Higher; (EHTH) (INTC) (SWKS) Lower (more...)

Jul 23, 2020 04:06 PM UPDATE: Oppenheimer Starts NuCana (NCNA) at Outperform

May 18, 2020 07:02 AM NuCana (NCNA) Reports Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic

May 5, 2020 05:39 PM NuCana (NCNA) Reports Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121)

Apr 2, 2020 04:03 PM NuCana (NCNA) Announces Update on Impact of COVID-19 on Clinical Studies

Mar 11, 2020 07:41 AM NuCana (NCNA) PT Lowered to $16 at H.C. Wainwright

Mar 10, 2020 04:02 PM NuCana (NCNA) Reports Prelim. Data from Phase II Study of Single-Agent Acelarin in Patients with Platinum-Resistant Ovarian Cancer

Mar 4, 2020 07:06 AM NuCana (NCNA) Announces Positive Opinion for Orphan Drug Designation in EU for Acelarin for Treatment of Patients with Biliary Tract Cancer